CNTX 6970
Alternative Names: CNTX-6970Latest Information Update: 27 Jun 2024
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Non-opioid analgesics; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammatory pain
Most Recent Events
- 11 Jun 2024 Massachusetts General Hospital completes phase-II clinical trial in Inflammatory pain (In adults, In the elderly) in USA (PO) (NCT05025787)
- 07 Dec 2022 Phase II development in Inflammatory pain is ongoing in USA (PO) (Centrexion Therapeutics pipeline, December 2022)
- 25 Oct 2021 Phase-II clinical trials in Inflammatory pain (In adults, In the elderly) in USA (PO) (NCT05025787)